CD163 Overview
Molecule Name
Scavenger receptor cysteine-rich type 1 protein M130
Synonyms
CD163,M130
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs1
Highest Development StageApproved
Target Synonym
CD163，M130，Scavenger receptor cysteine-rich type 1 protein M130，sCD163，CD163 Molecule，Hemoglobin Scavenger Receptor，CD163 Antigen，Macrophage-Associated Antigen，SCARI1，MM130
Background
Scavenger receptor cysteine-rich type 1 protein M130 (CD163) is also known as hemoglobin scavenger receptor, which is a scavenger receptor for the hemoglobin-haptoglobin complex. CD163 has also been shown to mark cells of monocyte/macrophage lineage. A soluble form of the receptor exists in plasma, commonly denoted sCD163. sCD163 is generated by ectodomain shedding of the membrane bound receptor. sCD163 is upregulated in a large range of inflammatory diseases including liver cirrhosis, type 2 diabetes, macrophage activation syndrome, Gaucher's disease, sepsis, HIV infection, rheumatoid arthritis and Hodgkin Lymphoma.
CD163 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| OR-2805 | OR-2805 | Phase 2 Clinical | OncoResponse Inc | Carcinoma, Non-Small-Cell Lung; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasm Metastasis; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tetrachlorodecaoxide | OXO-K993; WF-10; TCDO | Approved | Nuvox Pharma LLC | Oxoferin, Immunokine, WF10 | Thailand | Inflammation; Rhinitis, Allergic | null | 1997-01-01 | Diabetic Foot; HIV Infections; Inflammation; Rhinitis, Allergic | Details |